Results 41 to 50 of about 3,549 (185)
Evaluation of pegfilgrastim use at an academic medical center
, 2017 Purpose Pegfilgrastim is indicated to reduce the risk of febrile neutropenia. As a cost-savings initiative, Pegfilgrastim Process Guidelines were developed and implemented at a large, academic teaching institution to improve appropriate use of ...
Kathy Tang, Steven Gilmore, Alison Duffy
core +1 more source
BMC Cancer, 2008 Background Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in ...
Noga Stephen J +9 more
doaj +1 more source
Frontiers in Oncology, 2020 The mobilization of hematopoietic stem cells (HSCs) using granulocyte colony-stimulating factor is a classic method. Recently, a single injection of pegfilgrastim was used to mobilize CD34+ cells in some small-sample studies.
Jiali Li +22 more
doaj +1 more source
BMC Health Services Research, 2023 Background Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients ...
María Alejandra Larrarte-González +4 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang +15 more
wiley +1 more source
Pegfilgrastim in children with severe congenital neutropenia
, 2010 Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in ...
Francesca Fioredda +19 more
core +1 more source
Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Following promising results in a phase II trial evaluating GAMMA as salvage therapy for relapsed germ cell tumours (GCT) who had progressed on cisplatin‐based chemotherapy, the GAMMA regimen was adopted into clinical practice at St Bartholomew's Hospital.
Nasreen Abdul Aziz +3 more
wiley +1 more source
Journal of Neuroinflammation, 2011 Background Granulocyte colony stimulating factor (GCSF) is protective in animal models of various neurodegenerative diseases. We investigated whether pegfilgrastim, GCSF with sustained action, is protective in a mouse model of amyotrophic lateral ...
Giniatullina Raisa +11 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Chemoimmunotherapy is widely used as the first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), but treatment options for second‐line have not changed. Amrubicin monotherapy is used as the standard treatment for relapsed SCLC, but since chemoimmunotherapy became an additional indication for ES‐SCLC, the efficacy ...
Kei Sonehara +16 more
wiley +1 more source
Selective versus routine use of pegfilgrastim in dose-dense chemotherapy.
, 2014 149 Background: ASCO recommends CSFs such as pegfilgrastim for dose dense doxorubicin cyclophosphamide paclitaxel (ddACT) in breast cancer. It is unclear whether dose dense paclitaxel requires pegfilgrastim, and some community oncologists use ...
Jennifer Bishop +3 more
core +1 more source